1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Bone Disorders – Pipeline Review, H1 2013

Bone Disorders – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 61 pages

Bone Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Bone Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bone Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Disorders. Bone Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Disorders.
- A review of the Bone Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bone Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bone Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Bone Disorders 8
Bone Disorders Therapeutics under Development by Companies 10
Bone Disorders Therapeutics under Investigation by Universities/Institutes 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Bone Disorders Therapeutics - Products under Development by Companies 17
Bone Disorders Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Bone Disorders Therapeutics Development 20
GlaxoSmithKline plc 20
BioMarin Pharmaceutical Inc. 21
Cell Therapeutics, Inc. 22
Medivir AB 23
Calzada Limited 24
Fate Therapeutics, Inc. 25
Pharis Biotec GmbH 26
Se-cure Pharmaceuticals Ltd. 27
Bone Disorders - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ronacaleret hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
CT-1578 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
AOD-9604 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
MIV-710 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
MIV-711 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
BMN-111 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Wnt7a-­Based Protein Thearpeutics - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Allogenic Mesenchymal Stem Cells - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Drug For Bone Diseases and Osteoarthritis - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Drug For Autoimmune Bone Diseases - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
SC-661 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
P-881 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
SOM-0420 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Glucocorticoid-Induced Leucine Zipper - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Matrix Metalloprotease And Pro-Inflammatory Cytokine Inhibitors - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Allogeneic Stem Cells - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Matrix Embedded Stem Cells - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
maspin - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
phenothiazine Analog - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Drug For Bone Disorders - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Bone Disorders Therapeutics - Drug Profile Updates 55
Bone Disorders - Product Development Milestones 59
Featured News and Press Releases 59
Oct 08, 2012: NeoStem Announces Publication Of Data On Very Small Embryonic-Like Cells In Journal Stem Cells And Development 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61



List of Tables

Number of Products Under Development for Bone Disorders, H1 2013 8
Products under Development for Bone Disorders - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Number of Products under Development by Companies, H1 2013 (Contd..1) 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Mid Clinical Stage Development, H1 2013 14
Comparative Analysis by Early Clinical Stage Development, H1 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Development by Companies, H1 2013 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2013 19
GlaxoSmithKline plc, H1 2013 20
BioMarin Pharmaceutical Inc., H1 2013 21
Cell Therapeutics, Inc., H1 2013 22
Medivir AB, H1 2013 23
Calzada Limited, H1 2013 24
Fate Therapeutics, Inc., H1 2013 25
Pharis Biotec GmbH, H1 2013 26
Se-cure Pharmaceuticals Ltd., H1 2013 27
Assessment by Monotherapy Products, H1 2013 28
Assessment by Stage and Route of Administration, H1 2013 30
Assessment by Stage and Molecule Type, H1 2013 32
Bone Disorders Therapeutics - Drug Profile Updates 55



List of Figures

Number of Products under Development for Bone Disorders, H1 2013 8
Products under Development for Bone Disorders - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 13
Mid Clinical Stage Products, H1 2013 14
Early Clinical Stage Products, H1 2013 15
Discovery and Pre-Clinical Stage Products, H1 2013 16
Assessment by Monotherapy Products, H1 2013 28
Assessment by Route of Administration, H1 2013 29
Assessment by Stage and Route of Administration, H1 2013 30
Assessment by Molecule Type, H1 2013 31
Assessment by Stage and Molecule Type, H1 2013 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

  • $ 5100
  • Industry report
  • November 2016
  • by P&S Market Research

The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.